摘要
KIT或PDGFRA受体酪氨酸激酶功能获得性突变是大多数胃肠道间质瘤(GIST)的关键驱动因素。伊马替尼、舒尼替尼、安罗替尼、瑞戈非尼、瑞派替尼和阿伐替尼等酪氨酸激酶抑制剂的不断开发,极大程度上延长晚期GIST病人的总生存期。本文综述了近年来代表性酪氨酸激酶抑制剂在晚期胃肠道间质瘤治疗中的疗效(包括客观缓解率、疾病稳定率、中位无进展生存期)及常见不良事件,旨在为晚期GIST病人的治疗选择提供临床依据。
Gain-of-function mutations in KIT or PDGFRA receptor tyrosine kinase are key drivers of most gastrointestinal stromal tumor(GIST).The continuous development of tyrosine kinase inhibitors,such as imatinib,sunitinib,anlotinib,regorafenib,ripretinib and avapritinib,has greatly improved the overall survival of patients with advanced GIST.This article reviewed the efficacy(including objective response rate,disease stability rate,median progression free survival)and common adverse events of representative tyrosine kinase inhibitors in the treatment of advanced GIST in recent years,aiming to provide a clinical basis for the treatment options of patients with advanced GIST.
作者
唐海啸(综述)
张云
韩刚
龚航军(审校)
TANG Haixiao;ZHANG Yun;HAN Gang;GONG Hangjun(Department of Gastrointestinal Surgery,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medi-cine,Shanghai 201203,China)
出处
《外科理论与实践》
2025年第5期456-460,共5页
Journal of Surgery Concepts & Practice
关键词
胃肠道间质瘤
酪氨酸激酶抑制剂
KIT原癌基因
血小板衍生生长因子受体α
Gastrointestinal stromal tumor(GIST)
Tyrosine kinase inhibitor(TKI)
KIT proto-onco gene
Plateletderived growth factor receptor alpha(PDGFRA)
